Cellectar Biosciences Inc Total Assets
Cellectar Biosciences Inc total assets. Based on the latest financial reports, Cellectar Biosciences Inc (CLRB) holds total assets worth $14.98 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see CLRB market cap overview for the company's overall valuation and market capitalisation.
Total Assets of Cellectar Biosciences Inc (2004–2025)
Total assets of Cellectar Biosciences Inc from 2004 to 2025. This chart illustrates how Cellectar Biosciences Inc's total assets have evolved over time, based on quarterly financial data. See CLRB stock price and chart for real-time trading data and today's change.
Cellectar Biosciences Inc - Asset Composition Analysis
Cellectar Biosciences Inc Total Assets Breakdown (December 2025)
Cellectar Biosciences Inc total assets breakdown as of December 2025. Cellectar Biosciences Inc's total assets of $14.98 Million consist of 93.7% current assets and 6.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 88.1% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2004–2025)
This chart illustrates how Cellectar Biosciences Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore working capital position of Cellectar Biosciences Inc to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Cellectar Biosciences Inc's current assets represent 93.7% of total assets in 2025, a decrease from 94.5% in 2004.
- Cash Position: Cash and equivalents constituted 88.1% of total assets in 2025, up from 9.5% in 2004.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2004.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Cellectar Biosciences Inc Competitors by Total Assets
Key competitors of Cellectar Biosciences Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.46 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Bavarian Nordic
CO:BAVA
|
Denmark | Dkr14.95 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
Cellectar Biosciences Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.96 | 2.58 | 10.84 |
| Quick Ratio | 2.96 | 2.58 | 10.84 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $9.29 Million | $14.86 Million | $49.38 Million |
Cellectar Biosciences Inc - Advanced Valuation Insights
This section examines the relationship between Cellectar Biosciences Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.63 |
| Latest Market Cap to Assets Ratio | 0.35 |
| Asset Growth Rate (YoY) | -41.2% |
| Total Assets | $14.98 Million |
| Market Capitalization | $5.22 Million USD |
Valuation Analysis
Below Book Valuation: The market values Cellectar Biosciences Inc's assets below their book value (0.35x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Cellectar Biosciences Inc's assets decreased by 41.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Cellectar Biosciences Inc (2004–2025)
The table below shows the annual total assets of Cellectar Biosciences Inc from 2004 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $14.98 Million | -41.20% |
| 2024-12-31 | $25.47 Million | +110.96% |
| 2023-12-31 | $12.08 Million | -44.07% |
| 2022-12-31 | $21.59 Million | -41.97% |
| 2021-12-31 | $37.20 Million | -36.58% |
| 2020-12-31 | $58.66 Million | +378.82% |
| 2019-12-31 | $12.25 Million | -18.62% |
| 2018-12-31 | $15.05 Million | +16.96% |
| 2017-12-31 | $12.87 Million | -16.01% |
| 2016-12-31 | $15.32 Million | +101.74% |
| 2015-12-31 | $7.60 Million | -43.39% |
| 2014-12-31 | $13.42 Million | +96.88% |
| 2013-12-31 | $6.82 Million | -40.62% |
| 2012-12-31 | $11.48 Million | +8.66% |
| 2011-12-31 | $10.56 Million | +329.30% |
| 2010-12-31 | $2.46 Million | -72.45% |
| 2009-12-31 | $8.93 Million | +509.25% |
| 2008-12-31 | $1.47 Million | -86.80% |
| 2007-12-31 | $11.11 Million | -6.84% |
| 2006-12-31 | $11.92 Million | +141.43% |
| 2005-12-31 | $4.94 Million | +4448.82% |
| 2004-12-31 | $108.57K | -- |
About Cellectar Biosciences Inc
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States. The company's lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with re… Read more